FIELD: medicine; chemistry; pharmaceutics.
SUBSTANCE: invention refers to medicine and chemical-pharmaceutical industry and can be used for treating and/or preventing viral diseases by blocking activity of 3C-like viral proteases. A pharmaceutical composition for treating and/or preventing viral diseases by blocking activity of 3C-like viral proteases contains ritonavir or a pharmaceutically acceptable salt or solvate thereof in amount of 5.0 to 50.0 wt.% of the weight of the pharmaceutical composition. and nirmatrelvir or a pharmaceutically acceptable salt or solvate thereof in amount of 10.0 to 60.0 wt.% of the weight of the pharmaceutical composition, fillers, which are lactose or its monohydrate and microcrystalline cellulose in amount of 12.0 to 32.0 wt.% of the weight of the pharmaceutical composition, at least one disintegrant representing sodium croscarmellose in amount of 5.0 to 7.0 wt.% of the weight of the pharmaceutical composition, at least one binder selected from povidone and copovidone in amount of 5.0 to 15.0 wt.% of the weight of the pharmaceutical composition. Also disclosed is a medicinal agent containing said composition, and use of the pharmaceutical composition for preparing the medicinal agent.
EFFECT: obtained composition has improved stability of the combined formulation containing ritonavir and nirmatrelvir, provides reduced impurities formed during its storage, and improved pharmacokinetic characteristics of the combined formulation.
11 cl, 1 dwg, 4 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW COMBINED PHARMACEUTICAL COMPOSITION AND MEDICINAL PRODUCT FOR TREATMENT OF CORONAVIRUS INFECTION | 2022 |
|
RU2806643C1 |
| ANTI-RETROVIRAL COMBINATION | 2014 |
|
RU2675831C2 |
| ANTIRETROVIRAL COMBINATION | 2008 |
|
RU2531089C2 |
| NEW ANTIRETROVIRAL COMBINATION | 2008 |
|
RU2508105C2 |
| NOVEL FORMS OF (1R,2S,5S)-N-[(1S)-1-CYANO-2-[(3S)-2-OXOPYRROLIDIN-3-YL]ETHYL]-3-[(2S)-3,3-DIMETHYL-2-[(2,2,2-TRIFLUOROACETYL)AMINO]BUTANOYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE | 2023 |
|
RU2827154C1 |
| NOVEL FORMS OF (1R,2S,5S)-N-[(1S)-1-CYANO-2-[(3S)-2-OXOPYRROLIDIN-3-YL]ETHYL]-3-[(2S)-3,3-DIMETHYL-2-[(2,2,2-TRIFLUOROACETYL)AMINO]BUTANOYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE | 2023 |
|
RU2827157C1 |
| NOVEL FORMS OF (1R,2S,5S)-N-[(1S)-1-CYANO-2-[(3S)-2-OXOPYRROLIDIN-3-YL]ETHYL]-3-[(2S)-3,3-DIMETHYL-2-[(2,2,2-TRIFLUOROACETYL)AMINO]BUTANOYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE | 2023 |
|
RU2827358C1 |
| NOVEL FORMS OF (1R,2S,5S)-N-[(1S)-1-CYANO-2-[(3S)-2-OXOPYRROLIDIN-3-YL]ETHYL]-3-[(2S)-3,3-DIMETHYL-2-[(2,2,2-TRIFLUOROACETYL)AMINO]BUTANOYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE | 2023 |
|
RU2827158C1 |
| NOVEL FORMS OF (1R,2S,5S)-N-[(1S)-1-CYANO-2-[(3S)-2-OXOPYRROLIDIN-3-YL]ETHYL]-3-[(2S)-3,3-DIMETHYL-2-[(2,2,2-TRIFLUOROACETYL)AMINO]BUTANOYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE | 2023 |
|
RU2827357C1 |
| ANTIVIRAL PHARMACEUTICAL COMPOSITION CONTAINING FAVIPIRAVIR AND AMINO ACID HYDRATE AND/OR ITS PHARMACEUTICALLY ACCEPTABLE SALT | 2021 |
|
RU2789612C1 |
